Everything below concerns research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-24. Numbers and descriptions here follow the published literature rather than marketing material.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
| Property | Value | Notes |
|---|---|---|
| Amino acid count | 15 residues | Synthetic pentadecapeptide chain |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Molecular formula | C62H98N16O22 | Free peptide, without counter-ion |
| Theoretical mass | Approximately 1419.5 daltons | Varies slightly with adducts and counter-ions |
| Origin | Fragment of a human gastric juice protein | Source of the BPC designation |
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
=== Exercise === Early experimental evidence that skeletal muscle contraction induces vascular endothelial growth factor (VEGF) expression came from studies using electrically stimulated muscle. In a rat model, Hang et al. (1995) demonstrated that electrically stimulated skeletal muscle exhibited significant upregulation of VEGF expression, establishing skeletal muscle fibers as an active source of angiogenic signaling. This work preceded later exercise-training studies and contributed to the understanding of VEGF as a contraction-responsive factor involved in skeletal muscle angiogenesis.
Banauch D, Brümmer W, Ebeling W, Metz H, Rindfrey H, Lang H, Leybold K, Rick W, Staudinger HJ (1975). "[A glucose dehydrogenase for the determination of glucose concentrations in body fluids (author's transl)]". Z. Klin. Chem. Klin. Biochem. 13 (3): 101–7. PMID 810982. Brink NG; Miettinen, Jorma K.; Olsen, John; Virtanen, Artturi I.; Sörensen, Nils Andreas (1953). "Beef liver glucose dehydrogenase. 1. Purification and properties". Acta Chem. Scand. 7: 1081–1089. doi:10.3891/acta.chem.scand.07-1081. Pauly HE, Pfleiderer G (1976). "D-Glucose dehydrogenase from Bacillus megaterium M 1286: purification, properties and structure". Hoppe-Seyler's Z. Physiol. Chem. 356 (10): 1613–1623. doi:10.1515/bchm2.1975.356.2.1613. PMID 2530. Strecker HJ, Korkes S (1952). "Glucose dehydrogenase". J. Biol. Chem. 196 (2): 769–84. doi:10.1016/S0021-9258(19)52408-5. PMID 12981017. Thompson RE, Carper WR (1970). "Glucose dehydrogenase from pig liver. I. Isolation and purification". Biochim. Biophys. Acta. 198 (3): 397–406. doi:10.1016/0005-2744(70)90118-x. PMID 4392298.
Islam was introduced to the area early on by the first Muslims of Mecca fleeing prosecution during the first Hejira with Masjid al-Qiblatayn in Zeila being built before the Qiblah towards Mecca. It is one of the oldest mosques in Africa. In the late 9th century, Al-Yaqubi wrote that Muslims were living along the northern Somali seaboard. He also mentioned that the Adal Kingdom had its capital in the city. According to Leo Africanus, the Adal Sultanate was governed by local Somali dynasties and its realm encompassed the geographical area between the Bab-el-Mandeb and Cape Guardafui. It was thus flanked to the south by the Ajuran Empire and to the west by the Abyssinian Empire. Throughout the Middle Ages, Arab immigrants arrived in Somaliland, a historical experience which would later lead to the legendary stories about Muslim sheikhs such as Daarood and Ishaaq bin Ahmed (the purported ancestors of the Darod and Isaaq clans, respectively) travelling from Arabia to Somalia and marrying into the local Dir clan. The oldest writing in Somalia dates to this time, with the funerary inscription of Ḥajj Shānid in the al-Jami mosque in Barawa dating to 1104 or 1105 CE (year 498 AH). Although these medieval inscriptions are in Arabic, they were clearly written by people who were well-integrated into Somali culture and society. For example, an inscription from 1365 CE calls this year a Saturday year, using the traditional Somali calendar where years are named after the weekday on which the year begins.
Sources: en.wikipedia.org
== Genomic location and tissue expression == The ABCC1 gene, the gene that encodes the ABCC1 protein, is found on chromosome 16 within the nucleus. The protein resides intracellularly on the basolateral side of the plasma membrane which differs from other ATP-binding cassette transporters that are found on the apical side of the membrane. While ABCC1 is generally found throughout most tissues in humans, it is particularly prevalent in the lungs, spleen, testes, kidneys, placenta, thyroid, bladder, and adrenal glands. It is also found in the endothelium cells of the blood-brain barrier.
=== Historical === In 1888, the French botanist Gaston Bonnier demonstrated early experimental evidence for lichen symbiosis through his work with X. parietina (then called Parmelia parietina). He reported creating artificial lichen thalli by replacing the organism's natural algal partner (Protococcus viridis) with different algae species, including Protococcus botryoides and the filamentous reddish alga Trentepohlia abietina. While his methods foreshadowed modern microbiological techniques and represented a significant step for the time, modern assessments note critical limitations. His algal sources were not truly isolated (coming from other lichen thalli), and his "synthesized lichens" only vaguely resembled natural specimens, showing fungal hyphae surrounding algal cells but lacking true lichen morphology. In 1967, Richardson conducted early transplant experiments with X. parietina that helped establish methods for studying lichen adaptability. Using a novel technique of attaching lichen thalli to new substrates with resin glue, the study achieved a 96% survival rate in transplanted specimens. When coastal specimens (var. ectanea) were moved to farm roofs in Oxford, they showed significant morphological changes within 18 months, including increased lobe width from 0.8 mm to 2.4 mm. The study also demonstrated that parietin production could adapt to local conditions within six months, with transplanted specimens eventually matching the pigment levels of native populations.
==== Distribution ==== Pseudoephedrine, due to its lack of polar phenolic groups, is relatively lipophilic. This is a property it shares with related sympathomimetic and decongestant agents like ephedrine and phenylpropanolamine. These agents are widely distributed throughout the body and cross the blood–brain barrier. However, it is said that pseudoephedrine and phenylpropanolamine cross the blood-brain barrier only to some extent and that pseudoephedrine has limited central nervous system activity, suggesting that it is partially peripherally selective. The blood-brain barrier permeability of pseudoephedrine, ephedrine, and phenylpropanolamine is reduced compared to other amphetamines due to the presence of a hydroxyl group at the β carbon which decreases their lipophilicity. As such, they have a greater ratio of peripheral cardiovascular to central psychostimulant effect. Besides entering the brain, these substances also cross the placenta and enter breast milk. The plasma protein binding of pseudoephedrine has been reported to be approximately 21 to 29%. It is bound to α1-acid glycoprotein (AGP) and albumin (HSA).
Oganesson is a synthetic chemical element; it has symbol Og and atomic number 118. It was first synthesized in 2002 at the Joint Institute for Nuclear Research (JINR) in Dubna, near Moscow, Russia, by a joint team of Russian and American scientists. In December 2015, it was recognized as one of four new elements by the Joint Working Party of the international scientific bodies IUPAC and IUPAP. It was formally named on 28 November 2016. The name honors the nuclear physicist Yuri Oganessian, who played a leading role in the discovery of the heaviest elements in the periodic table. Oganesson has the highest atomic number and highest atomic mass of all known elements. On the periodic table of the elements it is a p-block element, a member of group 18, and the last member of period 7. Its only known isotope, oganesson-294, is highly radioactive, with a half-life of 0.7 ms. This half-life is too short for chemical studies. Because of relativistic effects, theoretical studies predict that it would be a solid at room temperature, and significantly reactive, unlike the other members of group 18 (the noble gases).
Sources: en.wikipedia.org
The peptide is synthetic, but its sequence matches a segment of a protein present in human gastric juice. It does not occur as a free fifteen-residue peptide in the body.
Rodents account for the large majority of published experiments. Human data are sparse and mostly observational, so cross-species extrapolation remains uncertain.
It is not an approved therapeutic in most jurisdictions. Regulatory status varies by country, and several places restrict it as a research chemical.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.